Marta Gustavo Nader, Moraes Fabio Ynoe, Feher Olavo, Vellutini Eduardo de Arnaldo Silva, Pahl Felix Hendrik, Gomes Marcos de Queiroz Teles, Cardoso Alberto Carlos Capel, Neville Iuri Santana, Hanna Samir Abdallah, Palhares Daniel Moore Freitas, Teixeira Manoel Jacobsen, Maldaun Marcos Vinícius Calfat, Pereira Allan Andresson Lima
Department of Radiation Oncology, Hospital Sírio-Libanês, Brazil.
Latin America Cooperative Oncology Group (LACOG), Brazil.
Lancet Reg Health Am. 2021 Sep 2;4:100066. doi: 10.1016/j.lana.2021.100066. eCollection 2021 Dec.
The majority of patients diagnosed with glioblastoma develop recurrent disease resulting in poor prognoses. The current study aimed to determine the survival rates of patients diagnosed with glioblastoma in Brazil accounting for the influence of age, treatment modalities, public and private practices, and educational level using a population-based national database.
Patients diagnosed with glioblastoma from 1999-2020 were identified from The Fundação Oncocentro de São Paulo database to create a retrospective cohort. Patients were described according to age, education level treatment modalities and medical practice. In a Cox proportional hazards model, controlled for confounding factors for overall survival, the hazard ratio and 95% CI of overall survival in adults was evaluated.
A total of 4,511 patients were included. The median lengths of survival for patients treated in the public and private settings were 8 and 17 months (p<0.001), respectively. Young patients had longer median overall survival (OS: 18 to 40 years, 41 to 60 years, 61 to 65 years, 66 to 70 years and over than 70 years was 22 months, 10 months, 6 months, 5 months, 4 months, respectively (p<0.001). In general, combined treatments were associated with higher median survival compared to monotherapy. The higher educational level, the higher median survival was observed (4 months for illiterate versus 14 months for university degree). In the multivariable analyses, the significant independent predictors for overall survival were practice setting, educational level, age and treatment modalities.
Public practice, older patients, less intensive treatment, and lower educational level were associated with worse survival outcomes in Brazilian glioblastoma patients.
大多数被诊断为胶质母细胞瘤的患者会出现疾病复发,导致预后不良。本研究旨在利用基于人群的国家数据库,确定巴西胶质母细胞瘤患者的生存率,并考虑年龄、治疗方式、公立和私立医疗机构以及教育水平的影响。
从圣保罗肿瘤中心基金会数据库中识别出1999年至2020年被诊断为胶质母细胞瘤的患者,以创建一个回顾性队列。根据年龄、教育水平、治疗方式和医疗实践对患者进行描述。在Cox比例风险模型中,对总生存的混杂因素进行控制,评估成人总生存的风险比和95%置信区间。
共纳入4511例患者。在公立和私立医疗机构接受治疗的患者的中位生存时间分别为8个月和17个月(p<0.001)。年轻患者的中位总生存期更长(OS:18至40岁、41至60岁、61至65岁、66至70岁以及70岁以上分别为22个月、10个月、6个月、5个月、4个月,p<0.001)。一般来说,与单一疗法相比,联合治疗与更高的中位生存期相关。教育水平越高,观察到的中位生存期越高(文盲为4个月,大学学位为14个月)。在多变量分析中,总生存的显著独立预测因素是医疗机构、教育水平、年龄和治疗方式。
在巴西胶质母细胞瘤患者中,公立医疗机构、老年患者、治疗强度较低和教育水平较低与较差的生存结果相关。